^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/28/2023
    Excerpt:
    Esophageal and Esophagogastric Junction Cancers...ADENOCARCINOMA….Useful in Certain Circumstances:…Selpercatinib for RET gene fusion-positive tumors
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

    Excerpt:
    Innovent Biologics, Inc...is pleased to see that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for selpercatinib (40mg & 80mg capsules) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion...